Home > Haematology > EHA 2021 > Thrombotic and Thrombocytopenic Disorders including COVID-19 related > Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia

Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia

Presented By
Prof. Dick Oepkes, Leiden University Medical Centre, the Netherlands
Conference
EHA 2021
Maternal prenatal screening and intervention can successfully prevent foetal or neonatal intracranial bleeding in foetal and neonatal alloimmune thrombocytopenia (FNAIT). To eradicate this disease, all pregnant women should be screened for risk factors. FNAIT is a devastating disease leading to bleeding events in foetuses and neonates (e.g. intracranial and intracerebral haemorrhage [ICH]). The disease is caused by the mother’s immune system targeting the foetus’ or neonate’s platelets, with maternal platelet-specific antibodies and (rarely) human leukocyte antigen (HLA) alloantibodies crossing the placenta. Prof. Dick Oepkes (Leiden University Medical Centre, the Netherlands) presented a clinician’s point of view on treatment and prophylaxis with the aim to prevent all bleeding in all foetuses and neonates [1]. Not every pregnant woman with HPA-1a antibodies (1:50) produces HPA-1a alloantibodies (1:400), and not every severe case of throm...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on